{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Autoantibody-driven uncontrolled terminal complement activation with membrane attack', 'complex MAC)-dependent lysis and activation, and C5a-dependent inflammation at the', 'neuromuscular junction (NMJ) causes AChR loss and failure of neuromuscular transmission.', 'Consistent with this model, both complement component (C) 3 (C3a and C3b) fragments and the', 'MAC C5b-9 have been found in NMJs of MG patients (Sahashi, 1978).', 'Taken together, the data support that uncontrolled terminal complement activation at the NMJ', 'plays a role in the destruction of post-synaptic structure. Rapid, complete, and sustained', 'inhibition of terminal complement activation is a biologically rational approach to prevent the', 'damage caused in patients with gMG.', '2.3.', 'Study Rationale', 'Ravulizumab (ALXN1210) was engineered from eculizumab (h5G1.1-mAb), a humanized', 'monoclonal Ab (mAb) that specifically binds with high affinity to the human terminal C5,', 'inhibiting C5 enzymatic cleavage and thereby preventing the generation of the', 'proinflammatory/prothrombotic mediators, such as MAC C5b-9, which are responsible for the', 'inflammatory consequences of terminal complement activation. Eculizumab is approved for the', 'treatment of gMG, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic', 'syndrome (aHUS), and neuromyelitis optica spectrum disorder (NMOSD) in many countries', 'worldwide under the trade name Soliris', 'Ravulizumab preserves immediate and complete C5 inhibition while providing sustained', 'complement inhibition throughout a prolonged dosing interval; it was specifically designed (and', 'has subsequently been proven) to have an increased half-life relative to eculizumab. Therefore,', 'ravulizumab requires less frequent (once every 8 weeks [q8w]) infusions relative to eculizumab', '(once every 2 weeks [q2w] infusions). Given that gMG is a chronic disease with a significant', 'treatment burden, the relative convenience of the ravulizumab dosing regimen may increase', 'patient satisfaction, increase treatment adherence, and ultimately, lead to improved health', 'outcomes.', 'Ravulizumab was designed based on comprehensive modelling and simulation analyses to', 'maintain efficacious concentrations across a longer dosing interval. The enhanced', 'pharmacokinetic (PK)/pharmacodynamic (PD) profile of ravulizumab, with fewer PK troughs,', 'than eculizumab, has the potential to improve therapeutic efficacy while maintaining a safety', 'profile similar to that of eculizumab. Furthermore, the q8w dosing regimen minimizes the risk of', 'incomplete complement inhibition. The infusion frequency is relatively low (6 infusions per', 'year) (Figure 1), which offers the potential for improved quality of life (QoL) through fewer', 'missed days of work or school, better treatment adherence, and improved accessibility.', 'Page 27 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Figure 1:', 'Ravulizumab Every 8 Weeks Dosage Regimen Versus Eculizumab Every', '2 Weeks Dosage Regimen', 'wo', 'W2', 'W10', 'W18', 'W26', 'W34', 'W42', 'Ravulizumab', 'Eculizumab', 'Ravulizumab offers a convenient dosing and immediate onset of action with effective and', 'complete terminal complement inhibition at the end of the first infusion. Additionally, the dose', 'regimen of ravulizumab has been optimized to reduce the exposure differences across the adult', 'body-weight range by utilizing a weight-based dosing paradigm that provides immediate,', 'complete, and sustained C5 inhibition over the entire dosing interval. Therefore, ravulizumab', 'minimizes the risk of inflammation, including C5a recruitment and activation of inflammatory', 'cells as well as direct MAC-complex induced damage of the motor neural endplate (Kusner,', '2008).', 'The proposed rationale for the ravulizumab posology for the gMG indication is highly consistent', 'with the approach used in dose-selection for eculizumab in the aHUS and gMG indications.', '2.4.', 'Benefit/Risk Assessment', 'Ravulizumab provides patients and physicians with an option for less frequent dosing, which', 'allows greater access to care for those patients who may not initiate treatment on eculizumab,', 'may discontinue eculizumab due to frequency of dosing, or who are currently receiving', 'eculizumab every 2 weeks.', '2.4.1.', 'Identified and Potential Risks', '2.4.1.1.', 'Identified Risk', '2.4.1.1.1. Neisseria meningitidis', 'Increased susceptibility to infection caused by Neisseria meningitidis (N meningitidis) is a', 'known risk associated with complement inhibition. The main risk associated with ravulizumab is', 'the risk of meningococcal infections. Specific risk mitigation measures are in place to address', 'this risk, as described in Section 8.3.6.', '2.4.1.2.', 'Potential Risks', '2.4.1.2.1. Immunogenicity', 'Administration of any therapeutic protein, including ravulizumab, may induce an immunogenic', 'response potentially resulting in antidrug antibodies (ADA). The spectrum of potential clinical', 'Page 28 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}